Lyell Immunopharma Q1 net loss $67M; cash $668M; two Phase 1 trials ongoing

Lyell Immunopharma, Inc.

2023-Q1 EPS reported -$0.27 revenue$65,000

GAAP net loss of $67.0M for Q1 2023, compared to $68.1M in Q1 2022; non-GAAP net loss $44.8M vs $50.0M.
Cash, equivalents and marketable securities of $668.0M as of March 31, 2023; cash runway into 2026.
Revenue $0.1M, down from $0.6M due to termination of GSK collaboration in December 2022.
Two Phase 1 trials (LYL797 CAR-T and LYL845 TIL) recruiting at 14 US sites; initial clinical data expected in 2024.
LYL119 IND submission expected in first half of 2024; abstract at ASGCT May 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lyell Immunopharma, Inc. reported the first quarter ended March 31, 2023 results: revenue $0.1 million, net income $67.0 million net loss.

Period: the first quarter ended March 31, 2023
Revenue: $0.1 million
Net income: $67.0 million net loss
Result: reported results

Exact text from the filing

First Quarter Financial Results Lyell reported a net loss of $67.0 million for the first quarter ended March 31, 2023, compared to a net loss of $68.1 million for the same period in 2022. Non‐GAAP net loss, which excludes non-cash stock-based compensation, non‐cash expenses related to the change in the estimated fair value of success payment liabilities and certain non-cash investment gains and charges, was $44.8 million for the first quarter ended March 31, 2023, compared to $50.0 million for the same period in 2022. Revenue • Revenue was $0.1 million for the first quarter ended March 31, 2023 compared to $0.6 million for the same period in 2022.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Lyell Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-015733

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.